Recent developments highlight clinical trial progress, regulatory approvals, leadership changes, and financial reporting for Pulse Biosciences.

• Pulse Biosciences initiated patient enrollment in the NANOPULSE-AF pivotal trial following a strong 96% procedural success in an earlier study [N1][N3].
• The company appointed Liane Teplitsky as Chief Operating Officer and expanded David Kenigsberg's role as full-time Chief Medical Officer in April 2026 [N2].
• Pulse Biosciences accelerated its cardiac catheter program after breakthrough atrial fibrillation data reported in March 2026 [N4].
• The company enrolled the first patient in a study of nPulse technology for thyroid microcarcinoma in March 2026 [N5].
• Pulse Biosciences reported a net loss for Q4 and full year 2025 but beat revenue estimates as of February 2026 [N6].
• The company shared positive first-in-human nPulse cardiac catheter data in February 2026 [N7].
• Pulse Biosciences won FDA IDE approval to launch the nPulse AF Ablation Study Trial in December 2025 [N8].

Pulse Biosciences has demonstrated progress in advancing its clinical pipeline with FDA IDE approvals and initiation of pivotal trials, including the NANOPULSE-AF study for atrial fibrillation. Positive early clinical data, such as a 96% procedural success rate in feasibility studies, supports the potential of its nPulse technology. The company’s strong liquidity position provides financial flexibility to support ongoing development and commercialization efforts. Leadership appointments aimed at strengthening operational and medical expertise may enhance execution capabilities.

Pulse Biosciences reported a significant net loss of $72.8 million for fiscal 2025, reflecting ongoing investment and development costs without current profitability. The company remains dependent on successful clinical trial outcomes and regulatory approvals to advance its product pipeline. As a smaller reporting company, it faces risks related to market acceptance, competition, and execution of commercialization strategies. The clinical and regulatory environment for medical technologies can be uncertain, and delays or adverse results could impact business prospects.

Pulse Biosciences' moat is derived from its proprietary medical technologies and ongoing clinical development programs, including the CellFX System and nPulse platform. The company has secured regulatory approvals such as FDA IDE for pivotal trials, which supports its competitive positioning. Its leadership team brings extensive experience in medical device commercialization and healthcare investment, which may aid in navigating regulatory and market challenges. However, as a smaller reporting company with ongoing clinical development, the company faces typical risks of medical technology firms including regulatory hurdles, clinical trial outcomes, and commercialization execution.

• Clinical and Regulatory Risk: The company’s future depends on successful completion of clinical trials and obtaining regulatory approvals. Delays or negative outcomes could adversely affect operations.
• Financial Risk: Pulse Biosciences reported net losses and relies on its cash reserves and potential financing to fund operations. Insufficient capital could constrain development and commercialization.
• Market Acceptance Risk: Even with regulatory approvals, the company must achieve market adoption of its technologies, which can be affected by competition, reimbursement, and physician acceptance.

• Pulse Biosciences, Inc. is a Delaware corporation headquartered in Miami, Florida.
• The company is publicly traded on Nasdaq under the ticker PLSE.
• Pulse Biosciences develops medical technologies, including the CellFX System and nPulse technology, targeting applications such as cardiac catheter ablation for atrial fibrillation and treatment of thyroid microcarcinoma.
• The company has initiated patient enrollment in the NANOPULSE-AF pivotal trial following a prior feasibility study with a 96% procedural success rate [N1][N3].
• Pulse Biosciences received FDA IDE approval to launch the nPulse AF Ablation Study Trial in December 2025 [N8].
• The company has enrolled the first patient in a study of nPulse technology for thyroid microcarcinoma [N5].
• Pulse Biosciences reported a net loss of $72.8 million for the fiscal year ended December 31, 2025, with a basic EPS of -$1.08 [S1][N6].
• As of December 31, 2025, the company held $80.7 million in cash and cash equivalents and had a current ratio of 10.53, indicating strong liquidity [S1].
• Leadership changes include the appointment of Liane Teplitsky as Chief Operating Officer in April 2026 and expansion of David Kenigsberg's role as full-time Chief Medical Officer [N2].
• The company accelerated its cardiac catheter program after breakthrough atrial fibrillation data reported in early 2026 [N4].
• Pulse Biosciences has a board of directors with significant experience in medical technology and healthcare investment, including Co-Chairman and CEO Paul A. LaViolette and Co-Chairman Robert W. Duggan [S1].
• The company’s CEO employment agreement includes performance-based equity vesting tied to market capitalization and GAAP product revenue milestones [S1].
• Pulse Biosciences is classified as a smaller reporting company and is not a shell company [S1].
• The company’s business risk oversight is managed by its board and committees, including audit, compensation, and governance committees [S1].